Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Nai-Kong Cheung
Sloan Kettering Inst Can Research, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Y-mAbs Therapeutics
Equity Interest - Publicly traded entity (e.g., stock, stock option, or other ownership interest)
Dr. Cheal and other co-inventors at MSK developed a targeted theranostic molecular radiotherapy method known as the DOTA-PRIT platform that is based on antibodies suitable for use in treating common human tumors. This study proposes using animal models of human colorectal cancer and human breast cancer to adapt the DOTAPRIT platform for safe and effective tumor-targeting of actinium-225, a highly potent alpha-emitting therapeutic isotope, with the ultimate goal of precision medicine in patients with advanced cancers.
Y-mAbs is a company specializing in antibody therapeutics. There is a business overlap with Y-mAbs because the company may have an interest in the research results.
DOTA-based pre-targeting of alpha emitters
Project Narrative We have developed a targeted theranostic molecular radiotherapy method known as the DOTA-PRIT platform that is based on antibodies suitable for use in treating common human tumors. Our studies in animal models have shown superior therapeutic index (TI), i.e., the ratio of tumor radiation dose to radiation to normal tissues. We propose using animal models of human colorectal cancer and human breast cancer to adapt the DOTA- PRIT platform for safe and effective tumor-targeting of actinium-225, a highly potent alpha-emitting therapeutic isotope, with the ultimate goal of precision medicine in patients with advanced cancers.
Filed on January 23, 2019.
Tell us what you know about Nai-Kong Cheung's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.